cetuximab + dasatinib

Cetuximab + dasatinib is a combination therapy that targets both epidermal growth factor receptor (EGFR) and Src family kinases. Cetuximab is a monoclonal antibody that inhibits EGFR, while dasatinib is a multi-targeted tyrosine kinase inhibitor with primary activity against Src family kinases and ABL. This combination has been investigated in clinical trials for various solid tumors including colorectal cancer, triple-negative breast cancer, and head and neck squamous cell carcinoma. The rationale for combining these agents is based on preclinical evidence suggesting that Src inhibition may help overcome resistance to EGFR inhibitors like cetuximab.

Other names

b-University of Pittsburgh-advanced solid malignanciesCetuximab plus DasatinibDasatinib and CetuximabNCT00388427 regimenNCT-00388427 regimenNCT 00388427 regimen